secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040532
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO
--------------------------------------------------------------------------------

- R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.
- Net loss $69.3M vs $37.0M in prior year; cash & marketable securities $150.4M at Dec 31, 2023.
- Completed $201M IPO in Jan 2024; management expects operations funded into 2026.
- FDA granted Breakthrough Therapy Designation for furmonertinib in NSCLC with EGFR exon 20 ins.
- Proof-of-concept data for furmonertinib in PACC mutations expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/0001104659-24-040532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/tm249692d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer